NEW YORK, NY / ACCESSWIRE / December 7, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Investors who purchased Gossamer securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/goss.
The investigation concerns whether Gossamer violated federal securities laws.
On December 6, 2022, Gossamer issued a press release "announc[ing] topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH)." Although the Company represented that seralutinib met the primary endpoint in the clinical trial, Wall Street analysts questioned its performance, noting that the therapy did not outperform Merck & Co. Inc's sotatercept product. On this news, Gossamer's stock price fell $6.93 per share, or 74.6%, to close at $2.36 per share on December 6, 2022.
If you are aware of any facts relating to this investigation or purchased Gossamer securities, you can assist this investigation by visiting the firm's site: www.bgandg.com/goss. You can also contact Peretz Bronstein or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC